DHODH and mesothelioma: Given that mesothelioma is poorly vascularized, resulting in limited glucose availability in situ (Ohta et al, 1999; Ostergaard et al, 2013), we further assessed the sensitivity to DHODH inhibitors under glucose-limited conditions.